Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) Stock Competitors & Peer Comparison
See SUPN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SUPN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUPN | $47.30 | +0.90% | 2.8B | 15.64 | $3.06 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SUPN vs TAK Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TAK's P/E ratio is 12.52. In terms of profitability, SUPN's ROE is -0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SUPN is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TAK's competition here
Haleon plc (NYSE: HLN)
SUPN vs HLN Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas HLN's P/E ratio is 18.28. In terms of profitability, SUPN's ROE is -0.10%, compared to HLN's ROE of +0.17%. Regarding short-term risk, SUPN is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SUPN vs TEVA Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TEVA's P/E ratio is 12.54. In terms of profitability, SUPN's ROE is -0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, SUPN is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
SUPN vs VTRS Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas VTRS's P/E ratio is 6.39. In terms of profitability, SUPN's ROE is -0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, SUPN is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SUPN vs ITCI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SUPN's ROE is -0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SUPN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
SUPN vs CTLT Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SUPN's ROE is -0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SUPN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SUPN vs ELAN Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ELAN's P/E ratio is 20.91. In terms of profitability, SUPN's ROE is -0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, SUPN is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SUPN vs RDY Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas RDY's P/E ratio is 20.30. In terms of profitability, SUPN's ROE is -0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, SUPN is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SUPN vs LNTH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas LNTH's P/E ratio is 16.93. In terms of profitability, SUPN's ROE is -0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, SUPN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SUPN vs AMRX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AMRX's P/E ratio is 19.62. In terms of profitability, SUPN's ROE is -0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, SUPN is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SUPN vs INDV Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas INDV's P/E ratio is 10.61. In terms of profitability, SUPN's ROE is -0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, SUPN is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SUPN vs RGC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas RGC's P/E ratio is -356.34. In terms of profitability, SUPN's ROE is -0.10%, compared to RGC's ROE of -2.32%. Regarding short-term risk, SUPN is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SUPN vs BHC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas BHC's P/E ratio is 1.58. In terms of profitability, SUPN's ROE is -0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, SUPN is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SUPN vs DCPH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SUPN's ROE is -0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SUPN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SUPN vs HCM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas HCM's P/E ratio is 4.59. In terms of profitability, SUPN's ROE is -0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SUPN is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SUPN vs AVDL Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SUPN's ROE is -0.10%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, SUPN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
SUPN vs EMBCV Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SUPN's ROE is -0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SUPN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SUPN vs DVAX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SUPN's ROE is -0.10%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, SUPN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
SUPN vs PRGO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PRGO's P/E ratio is 5.07. In terms of profitability, SUPN's ROE is -0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, SUPN is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SUPN vs ANIP Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ANIP's P/E ratio is 9.14. In terms of profitability, SUPN's ROE is -0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, SUPN is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SUPN vs TARO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TARO's P/E ratio is 30.05. In terms of profitability, SUPN's ROE is -0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SUPN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SUPN vs HROW Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas HROW's P/E ratio is 437.33. In terms of profitability, SUPN's ROE is -0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SUPN is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SUPN vs PAHC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PAHC's P/E ratio is 11.54. In terms of profitability, SUPN's ROE is -0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, SUPN is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
SUPN vs ALVO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ALVO's P/E ratio is -11.79. In terms of profitability, SUPN's ROE is -0.10%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, SUPN is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
SUPN vs CRON Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CRON's P/E ratio is 30.10. In terms of profitability, SUPN's ROE is -0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, SUPN is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SUPN vs ETON Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ETON's P/E ratio is -594.00. In terms of profitability, SUPN's ROE is -0.10%, compared to ETON's ROE of -0.06%. Regarding short-term risk, SUPN is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SUPN vs PCRX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PCRX's P/E ratio is 9.12. In terms of profitability, SUPN's ROE is -0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, SUPN is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SUPN vs PETQ Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SUPN's ROE is -0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SUPN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SUPN vs AMPH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AMPH's P/E ratio is 6.82. In terms of profitability, SUPN's ROE is -0.10%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, SUPN is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SUPN vs COLL Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas COLL's P/E ratio is 3.26. In terms of profitability, SUPN's ROE is -0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, SUPN is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
SUPN vs EVO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas EVO's P/E ratio is -3.09. In terms of profitability, SUPN's ROE is -0.10%, compared to EVO's ROE of -0.24%. Regarding short-term risk, SUPN is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SUPN vs IRWD Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas IRWD's P/E ratio is 5.54. In terms of profitability, SUPN's ROE is -0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, SUPN is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SUPN vs BDSI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SUPN's ROE is -0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SUPN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
SUPN vs EOLS Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas EOLS's P/E ratio is -25.71. In terms of profitability, SUPN's ROE is -0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, SUPN is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SUPN vs AQST Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AQST's P/E ratio is -6.93. In terms of profitability, SUPN's ROE is -0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, SUPN is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SUPN vs TLRY Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TLRY's P/E ratio is -4.32. In terms of profitability, SUPN's ROE is -0.10%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, SUPN is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SUPN vs CGC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CGC's P/E ratio is -0.62. In terms of profitability, SUPN's ROE is -0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, SUPN is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
SUPN vs KMDA Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas KMDA's P/E ratio is 19.66. In terms of profitability, SUPN's ROE is -0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SUPN is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SUPN vs TKNO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TKNO's P/E ratio is -23.84. In terms of profitability, SUPN's ROE is -0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SUPN is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SUPN vs ALIM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SUPN's ROE is -0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SUPN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
SUPN vs EMBC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas EMBC's P/E ratio is 1.83. In terms of profitability, SUPN's ROE is -0.10%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, SUPN is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
SUPN vs LNDC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SUPN's ROE is -0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, SUPN is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SUPN vs ACB Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ACB's P/E ratio is -7.80. In terms of profitability, SUPN's ROE is -0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SUPN is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SUPN vs ORGO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ORGO's P/E ratio is 60.33. In terms of profitability, SUPN's ROE is -0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, SUPN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
SUPN vs TYHT Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SUPN's ROE is -0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SUPN is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SUPN vs SIGA Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SIGA's P/E ratio is 10.63. In terms of profitability, SUPN's ROE is -0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SUPN is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
SUPN vs OGI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas OGI's P/E ratio is -4.96. In terms of profitability, SUPN's ROE is -0.10%, compared to OGI's ROE of -0.07%. Regarding short-term risk, SUPN is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SUPN vs LFCR Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas LFCR's P/E ratio is -4.46. In terms of profitability, SUPN's ROE is -0.10%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, SUPN is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SUPN vs REPH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas REPH's P/E ratio is -8.04. In terms of profitability, SUPN's ROE is -0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SUPN is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
SUPN vs DERM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas DERM's P/E ratio is -17.38. In terms of profitability, SUPN's ROE is -0.10%, compared to DERM's ROE of -0.36%. Regarding short-term risk, SUPN is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SUPN vs CRDL Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CRDL's P/E ratio is -5.41. In terms of profitability, SUPN's ROE is -0.10%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, SUPN is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SUPN vs THTX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas THTX's P/E ratio is -28.83. In terms of profitability, SUPN's ROE is -0.10%, compared to THTX's ROE of +0.17%. Regarding short-term risk, SUPN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SUPN vs ASRT Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SUPN's ROE is -0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SUPN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SUPN vs CPIX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CPIX's P/E ratio is -19.90. In terms of profitability, SUPN's ROE is -0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SUPN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SUPN vs SCTL Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SUPN's ROE is -0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SUPN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
SUPN vs BGM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas BGM's P/E ratio is -1.01. In terms of profitability, SUPN's ROE is -0.10%, compared to BGM's ROE of -0.07%. Regarding short-term risk, SUPN is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
SUPN vs PROC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PROC's P/E ratio is 1.53. In terms of profitability, SUPN's ROE is -0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SUPN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SUPN vs OPTN Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SUPN's ROE is -0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SUPN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SUPN vs ZOM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SUPN's ROE is -0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, SUPN is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SUPN vs GRVI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SUPN's ROE is -0.10%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, SUPN is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SUPN vs ZYBT Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, SUPN's ROE is -0.10%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, SUPN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
SUPN vs TLPH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TLPH's P/E ratio is -4.52. In terms of profitability, SUPN's ROE is -0.10%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, SUPN is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SUPN vs ZYNE Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SUPN's ROE is -0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SUPN is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
SUPN vs SSIC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SUPN's ROE is -0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, SUPN is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SUPN vs VLNS Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SUPN's ROE is -0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, SUPN is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
SUPN vs DRRX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SUPN's ROE is -0.10%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, SUPN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
SUPN vs INCR Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas INCR's P/E ratio is -2.23. In terms of profitability, SUPN's ROE is -0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SUPN is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SUPN vs JUPW Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SUPN's ROE is -0.10%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, SUPN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SUPN vs CPHI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CPHI's P/E ratio is -1.72. In terms of profitability, SUPN's ROE is -0.10%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, SUPN is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SUPN vs QLI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas QLI's P/E ratio is -4.92. In terms of profitability, SUPN's ROE is -0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SUPN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
SUPN vs HEXO Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SUPN's ROE is -0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SUPN is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SUPN vs RMTI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas RMTI's P/E ratio is -7.42. In terms of profitability, SUPN's ROE is -0.10%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, SUPN is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SUPN vs AYTU Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AYTU's P/E ratio is -1.23. In terms of profitability, SUPN's ROE is -0.10%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, SUPN is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SUPN vs TXMD Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas TXMD's P/E ratio is 105.96. In terms of profitability, SUPN's ROE is -0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SUPN is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SUPN vs CYTH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SUPN's ROE is -0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SUPN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SUPN vs EVOK Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SUPN's ROE is -0.10%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, SUPN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SUPN vs OPTH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas OPTH's P/E ratio is -17.38. In terms of profitability, SUPN's ROE is -0.10%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, SUPN is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SUPN vs ACRX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SUPN's ROE is -0.10%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, SUPN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
SUPN vs BFRIW Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, SUPN's ROE is -0.10%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, SUPN is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
SUPN vs COSM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas COSM's P/E ratio is -0.29. In terms of profitability, SUPN's ROE is -0.10%, compared to COSM's ROE of -0.96%. Regarding short-term risk, SUPN is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SUPN vs AGRX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SUPN's ROE is -0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SUPN is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SUPN vs NLTX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SUPN's ROE is -0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SUPN is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
SUPN vs LCI Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas LCI's P/E ratio is -0.04. In terms of profitability, SUPN's ROE is -0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SUPN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SUPN vs ADMP Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SUPN's ROE is -0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SUPN is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
SUPN vs YCBD Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas YCBD's P/E ratio is -1.49. In terms of profitability, SUPN's ROE is -0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SUPN is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SUPN vs GELS Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas GELS's P/E ratio is -1.14. In terms of profitability, SUPN's ROE is -0.10%, compared to GELS's ROE of -0.25%. Regarding short-term risk, SUPN is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
SUPN vs MNK Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas MNK's P/E ratio is -0.44. In terms of profitability, SUPN's ROE is -0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SUPN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SUPN vs FLGC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SUPN's ROE is -0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SUPN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
SUPN vs UPC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas UPC's P/E ratio is -0.75. In terms of profitability, SUPN's ROE is -0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, SUPN is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
SUPN vs SBFM Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SBFM's P/E ratio is -0.20. In terms of profitability, SUPN's ROE is -0.10%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, SUPN is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SUPN vs PLXP Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SUPN's ROE is -0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SUPN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
SUPN vs SHPH Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SHPH's P/E ratio is -0.20. In terms of profitability, SUPN's ROE is -0.10%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, SUPN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
SUPN vs ATNX Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SUPN's ROE is -0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SUPN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SUPN vs SNOA Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SNOA's P/E ratio is -1.16. In terms of profitability, SUPN's ROE is -0.10%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SUPN is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
SUPN vs PROCW Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas PROCW's P/E ratio is N/A. In terms of profitability, SUPN's ROE is -0.10%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, SUPN is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
SUPN vs RDHL Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas RDHL's P/E ratio is 0.12. In terms of profitability, SUPN's ROE is -0.10%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, SUPN is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
SUPN vs SXTC Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas SXTC's P/E ratio is 1.18. In terms of profitability, SUPN's ROE is -0.10%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, SUPN is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
SUPN vs YCBD-PA Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, SUPN's ROE is -0.10%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, SUPN is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
SUPN vs CYTHW Comparison August 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.8B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, SUPN is priced at $47.30 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 15.64, whereas CYTHW's P/E ratio is N/A. In terms of profitability, SUPN's ROE is -0.10%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, SUPN is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CYTHW's competition here